It is important to note that ARID1A mutations and HNF-1beta overexpression act at different stages of tumor development, genetic inactivation of ARID1A activating the carcinogenetic process, while epigenetic activation of HNF-1beta being involved in tumor phenotype and cancer progression [146]. Here, ARID1A is linked to cancer.